LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M

LENZ Therapeutics, Inc.

2026-Q1 EPS reported -$1.32 vs consensus -$1.09 ▼ miss (-21.0%)

Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.
Launched DTC campaign with Sarah Jessica Parker; website traffic up 10x; pilot TV advertising in April 2026.
Submitted MAA to EMA (March 2026) and MHRA (April 2026) for VIZZ; fourth ex-U.S. partnership with Lunatus in Jan 2026.
Net loss $41.5M ($1.32/share) vs. $14.6M ($0.53/share) in Q1 2025; cash $258.4M to fund operations to positive cash flow.
Sales force expanding from 88 to 117 by end of Q2 2026; launched ECP direct sales initiative in April 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LENZ Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.5 million, EPS $1.32 per share (basic and diluted).

Period: the first quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was $41.5 million
EPS: $1.32 per share (basic and diluted)
Result: reported results

Exact text from the filing

LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001815776-26-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.